BTK
5 drugsBruton Tyrosine Kinase
Predictive biomarker for patient selection in 12 indications
Understanding BTK
What it means: BTK is essential for B-cell receptor signaling and B-cell survival. Critical in B-cell malignancies like CLL and mantle cell lymphoma.
Why it matters: BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) revolutionized treatment of CLL, MCL, and Waldenström macroglobulinemia.
Testing: BTK is not tested for patient selection. BTK inhibitors used based on diagnosis. Resistance mutations (C481S) may be monitored.
5
Approved Drugs
12
Indications
5
Companies
BTK is a precision-medicine biomarker linked to 5 FDA-approved targeted drugs from 5 companies, spanning 12 indications including Previously untreated mantle cell lymphoma in patients ineligible for autologous hematopoietic stem cell transplantation (in combination with bendamustine and rituximab), Mantle cell lymphoma in patients who have received at least one prior therapy, Chronic lymphocytic leukemia. Explore the targeted therapies, indications, testing methods, and companies developing BTK drugs below.
Search BTK Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting BTK
BTK Indications
Previously untreated mantle cell lymphoma in patients ineligible for autologous hematopoietic stem cell transplantation (in combination with bendamustine and rituximab) Mantle cell lymphoma in patients who have received at least one prior therapy Chronic lymphocytic leukemia Small lymphocytic lymphoma Mantle Cell Lymphoma Chronic Lymphocytic Leukemia Waldenstrom Macroglobulinemia Marginal Zone Lymphoma Graft Versus Host Disease Chronic Spontaneous Urticaria Small Lymphocytic Lymphoma Immune Thrombocytopenia